Cytokeratin 7 (OV-TL 12/30) Mouse Monoclonal Antibody
Specialties: Anatomic Pathology
Anti-cytokeratin 7 reacts with proteins that are found in most ductal, glandular, transitional, and biliary duct epithelial cells. Cytokeratin 7 (CK7) labeling can help distinguish between lung,1 breast carcinomas, and urothelial carcinomas that typically stain positive, and colon and prostate carcinomas that typically lack CK7 expression.2-7 CK7 is a common marker of primary lung adenocarcinomas and is observed in other primary lung carcinomas and non-pulmonary carcinomas.1 Anti-cytokeratin 7 has also been useful in the differential diagnosis of ovarian neoplasms.8
- Jerome Marson, V et al. "Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade." Histopathology vol. 45,2 (2004): 125-34.
- Murray, Shawn K et al. "Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma." The American journal of surgical pathology vol. 28,9 (2004): 1154-62.
- Chu, P et al. "Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 13,9 (2000): 962-72.
- Logani, Sanjay et al. "Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications." The American journal of surgical pathology vol. 27,11 (2003): 1434-41.
- Ramalingam, Preetha et al. "Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features." Annals of diagnostic pathology vol. 7,2 (2003): 112-9.
- Roy, Somak, and Anil V Parwani. "Adenocarcinoma of the urinary bladder." Archives of pathology & laboratory medicine vol. 135,12 (2011): 1601-5.
- Han, A C, and R Duszak Jr. "Coexpression of cytokeratins 7 and 20 confirms urothelial carcinoma presenting as an intrarenal tumor." Cancer vol. 86,11 (1999): 2327-30.
- McCluggage, W G, and N Wilkinson. "Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features." Histopathology vol. 47,3 (2005): 231-47.
Specifications
- Reactivity: paraffin
- Control: Lung adenocarcinoma (Cytoplasmic); Salivary gland (Cytoplasmic)
- Dilution Range: 1:100-1:500 *
Package Inserts
IFU
- IVD Rev. 6.0 (CMC30729060)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25.0 mL predilute ready-to-use | 307M-90 |
| 0.1 mL concentrate | 307M-94 |
| 0.5 mL concentrate | 307M-95 |
| 1.0 mL concentrate | 307M-96 |
| 1.0 mL predilute ready-to-use | 307M-97 |
| 7.0 mL predilute ready-to-use | 307M-98 |
For in vitro diagnostic (IVD) use in Canada
| 25.0 mL predilute ready-to-use | 307M-90 |
| 0.1 mL concentrate | 307M-94 |
| 0.5 mL concentrate | 307M-95 |
| 1.0 mL concentrate | 307M-96 |
| 1.0 mL predilute ready-to-use | 307M-97 |
| 7.0 mL predilute ready-to-use | 307M-98 |
For in vitro diagnostic (IVD) use in Europe
| 25.0 mL predilute ready-to-use | 307M-90 |
| 0.1 mL concentrate | 307M-94 |
| 0.5 mL concentrate | 307M-95 |
| 1.0 mL concentrate | 307M-96 |
| 1.0 mL predilute ready-to-use | 307M-97 |
| 7.0 mL predilute ready-to-use | 307M-98 |
For research use only (RUO) in Japan
| 25.0 mL predilute ready-to-use (RUO) | 307M-90-RUO |
| 0.1 mL concentrate (RUO) | 307M-94-RUO |
| 0.5 mL concentrate (RUO) | 307M-95-RUO |
| 1.0 mL concentrate (RUO) | 307M-96-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 307M-97-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 307M-98-RUO |
To request information on this product in additional countries, please click the button below.
